Price T Rowe Associates Inc Arvinas, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Arvinas, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,853,716 shares of ARVN stock, worth $72.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,853,716
Previous 3,988,869
3.39%
Holding current value
$72.2 Million
Previous $106 Million
10.61%
% of portfolio
0.01%
Previous 0.01%
Shares
16 transactions
Others Institutions Holding ARVN
# of Institutions
229Shares Held
68.4MCall Options Held
226KPut Options Held
285K-
Vanguard Group Inc Valley Forge, PA7.01MShares$131 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$126 Million7.19% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$117 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY2.78MShares$52.1 Million1.09% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.71MShares$50.7 Million0.01% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $997M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...